Sugi Predict

Sugi Predict / Compounds / SCHEMBL170884

SCHEMBL170884

SCHEMBL170884

Cc1cccc(Oc2cccnc2)c1

nearest known ligand 0.75

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.75
▸ TDP1 Q9NUW8 2/20 0.75
▸ LYN P07948 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ CYP19A1 P11511 3/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ GRM5 P41594 2/20 0.50
▸ HTT P42858 2/20 0.49
▸ ACHE P22303 1/20 0.48
▸ CYP11B1 P15538 1/20 0.46
▸ CYP11B2 P19099 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ XDH P47989 1/20 0.46
▸ SLC22A12 Q96S37 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29851471 0.83 ALDH1A1 (0.55) LMNATDP1LYNALDH1A1GRM5
SCHEMBL30535283 0.82 LMNA (0.82) LMNATDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL676142 0.82 LMNA (0.82) LMNATDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL29746015 0.82 ALDH1A1 (0.72) LMNATDP1LYNALDH1A1SMN1; SMN2
SCHEMBL456868 0.82 ALDH1A1 (0.72) LMNATDP1LYNALDH1A1SMN1; SMN2
SCHEMBL29398372 0.82 ALDH1A1 (0.72) LMNATDP1LYNALDH1A1SMN1; SMN2
SCHEMBL11457992 0.81 LMNA (0.81) LMNATDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL169035 0.81 LMNA (0.62) LMNATDP1ALDH1A1CYP19A1SMN1; SMN2
SCHEMBL168838 0.81 ALDH1A1 (0.61) LMNATDP1LYNALDH1A1HTT
SCHEMBL8736575 0.80 LMNA (0.67) LMNATDP1ALDH1A1CYP19A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 — — EP disclosed
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
WO-2021072203-A1 TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021011834-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-01-21 — — WO disclosed
WO-2020255020-A1 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 — — WO disclosed
WO-2020245372-A1 HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR Janssen Sciences Ireland Unlimited Company (IE) 2020-12-10 — — WO disclosed
EP-1641759-B1 MALONAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-12 — — EP disclosed
EP-1643991-B1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-03-12 — — EP disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 — — US disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 — — US disclosed
US-20070213374-A1 Malonamide Derivatives MERCK PATENT GMBH (DE) 2007-09-13 — — US disclosed
US-20070213374-A1 Malonamide Derivatives MERCK PATENT GMBH (DE) 2007-09-13 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 — — US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 — — US disclosed
US-20070093529-A1 Diacylhydrazine derivatives MERCK PATENT GMBH (DE) 2007-04-26 — — US disclosed
US-20070093529-A1 Diacylhydrazine derivatives MERCK PATENT GMBH (DE) 2007-04-26 — — US disclosed
US-20070010560-A1 angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis MERCK PATENT GMBH (DE) 2007-01-11 — — US disclosed
US-20070010560-A1 angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis MERCK PATENT GMBH (DE) 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS LMNA 2867/4885TDP1 835/4885LYN 153/4885
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors BRAF, RAF1, ARAF LMNA 2964/4885TDP1 2653/4885LYN 698/4885
US-20070010560-A1 angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis BRAF, RAF1, VEGFA LMNA 3781/4885TDP1 3048/4885LYN 319/4885
US-20070093529-A1 Diacylhydrazine derivatives BRAF, RAF1, NRAS LMNA 3800/4885TDP1 1410/4885LYN 157/4885
US-20130158076-A1 Methylene Urea Derivatives BRAF, RAF1, CMPK1 LMNA 3748/4885TDP1 2246/4885LYN 1378/4885
US-20070213374-A1 Malonamide Derivatives RAF1, BRAF, ARAF LMNA 3349/4885TDP1 1686/4885LYN 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.